1. Home
  2. DLPN vs MBRX Comparison

DLPN vs MBRX Comparison

Compare DLPN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dolphin Entertainment Inc.

DLPN

Dolphin Entertainment Inc.

HOLD

Current Price

$1.13

Market Cap

14.6M

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$0.54

Market Cap

12.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLPN
MBRX
Founded
1996
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.6M
12.7M
IPO Year
2008
2016

Fundamental Metrics

Financial Performance
Metric
DLPN
MBRX
Price
$1.13
$0.54
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
6.3K
585.0K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
77.87
N/A
EPS
N/A
N/A
Revenue
$56,699,389.00
N/A
Revenue This Year
$14.73
N/A
Revenue Next Year
$7.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.70
N/A
52 Week Low
$1.02
$0.16
52 Week High
$1.88
$7.98

Technical Indicators

Market Signals
Indicator
DLPN
MBRX
Relative Strength Index (RSI) 44.92 33.99
Support Level $1.06 $0.16
Resistance Level $1.20 $0.67
Average True Range (ATR) 0.05 0.08
MACD -0.01 0.03
Stochastic Oscillator 29.37 9.21

Price Performance

Historical Comparison
DLPN
MBRX

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing, and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials. The company operates within the U.S.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: